Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

T790M mutation

- PMLiVE

Trial backs role for Lynparza in second-line prostate cancer

Demonstrates potential significant benefit in treatment of disease

- PMLiVE

AZ and Novartis ‘most exposed’ to Senate pricing proposals

Most expensive therapies will be penalised

- PMLiVE

Lynparza cleared as ovarian cancer maintenance therapy on Cancer Drugs Fund

Deal done with NHS England just weeks after EU approval

- PMLiVE

AstraZenca to appeal NICE rejection of Tagrisso

Pfizer’s Vizimpro wins recommendation

- PMLiVE

AZ’s Imfinzi joins immunotherapy drive in small cell lung cancer

Tecentriq the leader in setting

25 Women Leaders in UK Healthcare

Women trailblazers helping to shape the future of healthcare (Part 1)

- PMLiVE

Lynparza scores approval for first line ovarian use in Europe

Partners plan further expansion

- PMLiVE

AZ says Farxiga cuts kidney disease in type 2 diabetes

Helps in SGLT2 inhibitor battle with Jardiance

- PMLiVE

AZ reports stellar results for Lynparza in pancreatic cancer

Plans to file as soon as possible

- PMLiVE

AZ invests more in IO with Transgene oncolytic virus deal

Opportunity for combinations with IO pipeline

- PMLiVE

Brexit clock ticking once again, UK heads for European elections

New deadline gives pharma more time, but no more clarity

- PMLiVE

Lynparza could soon add first line ovarian use in Europe

Also first PARP inhibitor launched in China

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links